FIELD: biotechnology.
SUBSTANCE: invention relates to a sirtuin activator – decapeptide-12, which modulates the expression of a sirtuin gene in a skin cell. The treatment of epidermal keratinocyte precursor cells with 100 mcM decapeptide-12 enhanced transcription of SIRT1 by 141±11% compared to reference cells, while levels of SIRT3, SIRT6, and SIRT7 were increased by 121±13%, 147±8%, and 95.4±14%, respectively.
EFFECT: decapeptide-12 activated sirtuin transcription to a level similar to oxyresveratrol, but with reduced cytotoxicity.
20 cl, 6 dwg, 10 tbl
